Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

by Avigan, David E , Green, Damian , Munshi, Nikhil C , Vij, Ravi , Nooka, Ajay K , Krishnan, Amrita , Gray, Lissa , Shah, Nina , Manasanch, Elisabet , Aiello, Jack , Ganapathi, Karthik , Chari, Ajai , Rapoport, Aaron P , Berdeja, Jesus G , Smith, Eric L , Dhodapkar, Madhav , Cohen, Adam D , Lin, Yi , Borrello, Ivan M

in Antibodies / antineoplastic protocols / Blood cancer / Cancer / Clinical medicine / Consensus / FDA approval / guidelines as topic / hematological neoplasms / Hematology / Humans / Immunomodulators / Immunotherapy / Immunotherapy - methods / Literature reviews / Multiple myeloma / Multiple Myeloma - drug therapy / Oncology / Patients / Position and Guidelines / Position article and guidelines / Quality of life / receptors, chimeric antigen / Stem cells / Transplants & implants

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

2020

Confirm

Do you wish to request the book?

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Avigan, David E,

Green, Damian,

Munshi, Nikhil C,

Vij, Ravi,

Nooka, Ajay K,

Krishnan, Amrita,

Gray, Lissa,

Shah, Nina,

Manasanch, Elisabet,

Aiello, Jack,

Ganapathi, Karthik,

Chari, Ajai,

Rapoport, Aaron P,

Berdeja, Jesus G,

Smith, Eric L,

Dhodapkar, Madhav,

Cohen, Adam D,

Lin, Yi,

Borrello, Ivan M

2020

Overview

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor (CAR) T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.

Share this book

Add to My Shelf

Publisher

BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group

Subject

Antibodies

/ antineoplastic protocols

/ Cancer